Yale Catriona's most recent trade in Akero Therapeutics Inc was a trade of 10,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2025 | 10,000 | 131,205 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 16 Jul 2025 | 10,000 | 101,488 (0%) | 0% | 19.9 | 198,700 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 52.86 per share. | 16 Jul 2025 | 8,658 | 92,830 (0%) | 0% | 52.9 | 457,705 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 53.47 per share. | 16 Jul 2025 | 1,342 | 91,488 (0%) | 0% | 53.5 | 71,762 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 23.87 per share. | 30 Jun 2025 | 890 | 91,488 (0%) | 0% | 23.9 | 21,243 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 54.84 per share. | 18 Jun 2025 | 1,633 | 90,598 (0%) | 0% | 54.8 | 89,554 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 16 Jun 2025 | 10,000 | 102,231 (0%) | 0% | 21.1 | 211,000 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 53.78 per share. | 16 Jun 2025 | 6,210 | 96,021 (0%) | 0% | 53.8 | 333,974 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 54.80 per share. | 16 Jun 2025 | 2,895 | 93,126 (0%) | 0% | 54.8 | 158,643 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.52 per share. | 16 Jun 2025 | 895 | 92,231 (0%) | 0% | 55.5 | 49,690 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 54.00 per share. | 10 Jun 2025 | 2,803 | 92,231 (0%) | 0% | 54.0 | 151,351 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 15 May 2025 | 10,000 | 105,034 (0%) | 0% | 21.1 | 211,000 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.91 per share. | 15 May 2025 | 4,384 | 95,034 (0%) | 0% | 39.9 | 174,948 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 38.20 per share. | 15 May 2025 | 2,837 | 102,197 (0%) | 0% | 38.2 | 108,371 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.46 per share. | 15 May 2025 | 2,779 | 99,418 (0%) | 0% | 39.5 | 109,659 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 9,073 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 15 Apr 2025 | 9,073 | 104,107 (0%) | 0% | 21.1 | 191,440 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 37.80 per share. | 15 Apr 2025 | 7,873 | 96,234 (0%) | 0% | 37.8 | 297,623 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 38.62 per share. | 15 Apr 2025 | 1,200 | 95,034 (0%) | 0% | 38.6 | 46,339 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 17 Mar 2025 | 10,000 | 105,034 (0%) | 0% | 21.1 | 211,000 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 44.70 per share. | 17 Mar 2025 | 8,201 | 96,833 (0%) | 0% | 44.7 | 366,560 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 45.05 per share. | 17 Mar 2025 | 1,799 | 95,034 (0%) | 0% | 45.1 | 81,045 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 44.88 per share. | 12 Mar 2025 | 614 | 95,034 (0%) | 0% | 44.9 | 27,556 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 18 Feb 2025 | 10,000 | 105,648 (0%) | 0% | 21.1 | 211,000 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.79 per share. | 18 Feb 2025 | 9,100 | 96,548 (0%) | 0% | 49.8 | 453,089 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.63 per share. | 18 Feb 2025 | 900 | 95,648 (0%) | 0% | 50.6 | 45,571 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 27 Jan 2025 | 49,074 | 144,722 (0%) | 0% | 21.1 | 1,035,461 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 57.02 per share. | 27 Jan 2025 | 27,340 | 95,648 (0%) | 0% | 57.0 | 1,559,036 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.15 per share. | 27 Jan 2025 | 25,907 | 118,815 (0%) | 0% | 55.2 | 1,428,823 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 27 Jan 2025 | 21,569 | 149,238 (0%) | 0% | 21.1 | 454,890 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 20,928 | 52,785 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 20,000 | 33,421 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.16 per share. | 27 Jan 2025 | 17,000 | 132,238 (0%) | 0% | 55.2 | 937,652 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 27 Jan 2025 | 16,849 | 112,497 (0%) | 0% | 0.6 | 10,362 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 16,849 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 27 Jan 2025 | 15,172 | 127,669 (0%) | 0% | 6.4 | 96,555 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 15,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.95 per share. | 27 Jan 2025 | 14,467 | 104,348 (0%) | 0% | 56.0 | 809,429 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 55.95 per share. | 27 Jan 2025 | 9,250 | 122,988 (0%) | 0% | 55.9 | 517,528 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 9,074 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 57.01 per share. | 27 Jan 2025 | 8,700 | 95,648 (0%) | 0% | 57.0 | 495,961 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 641 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Yale Catriona | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 73,700 | 73,700 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Yale Catriona | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 24,300 | 95,648 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 16 Dec 2024 | 9,074 | 104,722 (0%) | 0% | 21.1 | 191,461 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 9,074 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Yale Catriona | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.11 per share. | 16 Dec 2024 | 9,074 | 95,648 (0%) | 0% | 29.1 | 264,117 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.79 per share. | 10 Dec 2024 | 2,810 | 71,348 (0%) | 0% | 30.8 | 86,520 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 15 Nov 2024 | 9,061 | 83,219 (0%) | 0% | 21.1 | 191,187 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 9,061 | 53,421 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.69 per share. | 15 Nov 2024 | 8,761 | 74,458 (0%) | 0% | 27.7 | 242,627 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 28.82 per share. | 15 Nov 2024 | 300 | 74,158 (0%) | 0% | 28.8 | 8,647 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 06 Nov 2024 | 10,000 | 84,158 (0%) | 0% | 0.6 | 6,150 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 06 Nov 2024 | 10,000 | 74,158 (0%) | 0% | 35.2 | 351,890 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 8,890 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 1,110 | 16,849 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 30 Oct 2024 | 15,485 | 89,643 (0%) | 0% | 21.1 | 326,734 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 15,485 | 41,781 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.62 per share. | 30 Oct 2024 | 15,485 | 74,158 (0%) | 0% | 32.6 | 505,105 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.53 per share. | 30 Oct 2024 | 4,515 | 74,158 (0%) | 0% | 32.5 | 146,855 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 30 Oct 2024 | 4,515 | 78,673 (0%) | 0% | 21.1 | 95,267 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 4,515 | 57,266 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 14 Oct 2024 | 14,825 | 90,119 (0%) | 0% | 0.6 | 9,117 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.50 per share. | 14 Oct 2024 | 14,525 | 75,594 (0%) | 0% | 30.5 | 442,954 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 10,000 | 17,959 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 14 Oct 2024 | 6,136 | 74,158 (0%) | 0% | 30.0 | 184,258 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 5,000 | 8,890 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 14 Oct 2024 | 5,000 | 80,294 (0%) | 0% | 0.6 | 3,075 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 4,825 | 13,890 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.93 per share. | 14 Oct 2024 | 300 | 75,294 (0%) | 0% | 30.9 | 9,278 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 19 Sep 2024 | 5,500 | 80,794 (0%) | 0% | 0.6 | 3,383 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 5,500 | 27,959 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.65 per share. | 19 Sep 2024 | 5,500 | 75,294 (0%) | 0% | 27.7 | 152,086 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 3,871 | 33,459 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 16 Sep 2024 | 3,871 | 75,294 (0%) | 0% | 27.6 | 106,685 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 16 Sep 2024 | 3,871 | 79,165 (0%) | 0% | 0.6 | 2,381 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 16 Sep 2024 | 2,485 | 77,779 (0%) | 0% | 0.6 | 1,528 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,485 | 39,367 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.52 per share. | 16 Sep 2024 | 2,485 | 75,294 (0%) | 0% | 27.5 | 68,375 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,037 | 37,330 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 16 Sep 2024 | 2,037 | 75,294 (0%) | 0% | 27.5 | 56,115 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 16 Sep 2024 | 2,037 | 77,331 (0%) | 0% | 0.6 | 1,253 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 10 Sep 2024 | 637 | 75,294 (0%) | 0% | 26.2 | 16,677 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 949 | 18,715 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.61 per share. | 03 Sep 2024 | 949 | 75,931 (0%) | 0% | 27.6 | 26,206 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 03 Sep 2024 | 949 | 76,880 (0%) | 0% | 0.6 | 584 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 23 Aug 2024 | 8,851 | 84,782 (0%) | 0% | 0.6 | 5,443 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 8,851 | 24,864 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.53 per share. | 23 Aug 2024 | 8,851 | 75,931 (0%) | 0% | 27.5 | 243,641 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 5,200 | 19,664 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 23 Aug 2024 | 5,200 | 75,931 (0%) | 0% | 27.5 | 143,073 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 23 Aug 2024 | 5,200 | 81,131 (0%) | 0% | 0.6 | 3,198 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 19.94 per share. | 28 Jun 2024 | 1,064 | 75,931 (0%) | 0% | 19.9 | 21,217 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 22.64 per share. | 11 Jun 2024 | 2,825 | 74,867 (0%) | 0% | 22.6 | 63,961 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 28.33 per share. | 13 Mar 2024 | 723 | 77,692 (0%) | 0% | 28.3 | 20,483 | Common Stock |
| Akero Therapeutics Inc | Catriona Yale | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.49 per share. | 04 Mar 2024 | 20,646 | 78,415 (0%) | 0% | 35.5 | 732,727 | Common Stock |